Clinical trials: Disorder, Mood
Post Acute COVID-19 Syndrome
Digital Health Intervention Based on Artificial Intelligence to Support the Personalized Recovery of Long COVID Patients Affected by Fatigue (AIDA)
The AIDA feasibility study builds upon mental health and technology acceptance theoretical frameworks. It examines the feasibility of a mobile-based digital program to support patients with long covid affected by fatigue.
- Trial name
- AIDA (NCT05483829)
- Testing
- Adhera® Fatigue for Long COVID program
- Where
- Spain
- Volunteers
- 15 people
- Sponsor
- Adhera Health, Inc.
Mood Disturbance, Mood Change
Mood and Cognitive Effects of Psilocybin in Healthy Participants
This study is seeking to find the optimal microdose or low dose of psilocybin (magic mushrooms) that provides general enhancements to mood, memory, sleep, and other measures of general well-being without any hallucinogenic…
- Conditions
- Mood Disturbance, Mood Change, Sleep Disturbance, Drug Effect
- Trial name
- MELO (NCT05252598)
- Testing
- Psilocybin, Inonotus Obliquus Whole Extract
- Volunteers
- healthy volunteers welcome
- Sponsor
- Optimi Health Corporation
Depressive Disorder, Major, Diabetic Neuropathies
Study Evaluating the Potential of DVS SR to Inhibit the CYP2D6 Pathway
To evaluate the effects of multiple oral doses of desvenlafaxine sustained release (DVS SR) and paroxetine on the biotransformation of codeine to morphine in healthy subjects.
- Conditions
- Depressive Disorder, Major, Diabetic Neuropathies, Fibromyalgia, Vasomotor Symptoms
- Trial name
- NCT00456898
- Testing
- desvenlafaxine sustained release (DVS SR), Paroxetine, Codeine
- Volunteers
- 40 people, healthy volunteers welcome
- Sponsor
- Wyeth is now a wholly owned subsidiary of Pfizer
Postpartum Depression
A Long-Term Study of Patient-Reported Changes in Postpartum Depression Symptoms in People Starting Zuranolone
In this study, researchers will learn how postpartum depression symptoms may change after people first start taking zuranolone. This is a drug available for doctors to prescribe for people with postpartum depression, also known…
- Trial name
- NCT07398469
- Testing
- Zuranolone
- Where
- United States
- Volunteers
- 300 people
- Sponsor
- Biogen
Major Depressive Disorder (MDD), IBNI617
Probiotic IBNI617 for Moderate to Severe Depression
IBNI617 is a live biotherapeutic product(LBP). This is a randomized, double-blind, placebo-controlled, parallel-group Phase II clinical trial to evaluate the efficacy and safety of IBNI617 in adult patients with major depressive…
- Trial name
- NCT07728253
- Testing
- Live biotherapeutic product
- Where
- China
- Volunteers
- 148 people
- Sponsor
- IBIOME BIOTECHNOLOGY CO., LTD
Major Depressive Disorder
BTRX-246040 Administered Once Daily to Patients With Major Depressive Disorder
This study will determine the efficacy, safety, and tolerability of a once-daily (QD) dose of up to 80 mg of BTRX-246040 for 8 weeks in participants with MDD.
- Trial name
- NCT03193398
- Testing
- BTRX-246040 oral capsule(s)
- Where
- 8 sites in United States
- Volunteers
- 104 people
- Sponsor
- BlackThorn Therapeutics, Inc.
Major Depressive Disorder
Study of Safety & Tolerability of OPC-34712 as Adjunctive Therapy in Treatment of Adult Patients With Major Depressive Disorder
The purpose of this study is to assess the long-term safety, tolerability and efficacy of oral OPC-34712 as adjunctive therapy in the treatment of adult patients with Major Depressive Disorder (MDD).
- Trial name
- NCT01447576
- Testing
- ADT, OPC-34712
- Where
- 32 sites in United States
- Volunteers
- 1,036 people
- Sponsor
- Otsuka Pharmaceutical Development & Commercialization, Inc.
Major Depressive Disorder (MDD)
The Study of Ammoxetine Hydrochloride Enteric-coated Tablets in Subjects With Depression
The purpose of this study is to evaluate the efficacy and safety of Ammoxetine hydrochloride enteric-coated tablets in subjects with depression.
- Trial name
- Ammoxetine (NCT05762458)
- Testing
- Ammoxetine
- Volunteers
- 240 people
- Sponsor
- CSPC ZhongQi Pharmaceutical Technology Co., Ltd.
Mania, Bipolar Disorder
Efficacy and Safety of Seroquel and Lithium as Monotherapy in Acute Mania Treatment in Bipolar Disorder Patients
This is a randomised, double blind, double dummy, multicentre, parallel-group study to compare the efficacy and safety of quetiapine and lithium used as monotherapy in the treatment of mania in patients hospitalised for an acute…
- Trial name
- STAR (NCT00448578)
- Testing
- Quetiapine Fumarate, Lithium
- Where
- 6 sites in China
- Volunteers
- 150 people
- Sponsor
- AstraZeneca
Depressive Disorder, Treatment-Resistant
Pre-Approval Access to Esketamine Nasal Spray for the Treatment of Treatment-Resistant Depression (TRD)
This is a pre-approval access program (PAAP) for eligible participants. The main purpose of this program is to provide access to esketamine nasal spray to eligible participant with treatment-resistant depression (TRD), who have…
- Trial name
- NCT03829579
- Testing
- Esketamine
- Sponsor
- Janssen Research & Development, LLC
Major Depressive Disorder
A Study to Evaluate the Efficacy and Safety of MIN-117 in Adult Patients With Major Depressive Disorder
MIN-117C03 is a 6-week, 3-arm, randomized, double-blind, placebo controlled study to investigate the safety and efficacy of MIN-117 in male and female patients with Major Depressive Disorder, aged 18 to 65 years.
- Trial name
- NCT03446846
- Testing
- MIN-117 5.0 mg, MIN-117 2.5 mg
- Where
- 47 sites in United States, Bulgaria and 5 more
- Volunteers
- 360 people
- Sponsor
- Minerva Neurosciences
Stress, Healthy Subjects
The Effects of Chicory Root-derived Prebiotic on Mood and Stress Responsiveness in Healthy Adults With Mild to Moderate Levels of Stress and Anxiety
Emerging evidence from preclinical research suggests that prebiotic fibres may play a beneficial role in supporting mental health through modulation of the gut-brain axis-a complex communication network linking the…
- Conditions
- Stress, Healthy Subjects, Anxiety, Mild to Moderate
- Trial name
- PRIME (NCT07058324)
- Testing
- Prebiotic fiber
- Where
- Germany
- Volunteers
- 204 people, healthy volunteers welcome
- Sponsor
- Beneo-Institute
Major Depressive Disorder
The Objective of This Study is to Evaluate the Efficacy, Safety and Tolerability of Cariprazine as an Adjunctive Treatment to Antidepressant Therapy (ADT) in Patients With Major Depressive Disorder (MDD) Who Have Had an Inadequate Response to Antidepressants Alone
The objective of this study is to evaluate the efficacy, safety and tolerability of cariprazine as an adjunctive treatment to antidepressant therapy (ADT) in patients with MDD who have had an inadequate response to…
- Trial name
- NCT03739203
- Testing
- Cariprazine, Antidepressant Therapy (ADT)
- Where
- 112 sites in United States, Canada and 6 more
- Volunteers
- 752 people
- Sponsor
- AbbVie
Major Depressive Disorder
A Study Evaluating Duloxetine in Patients Hospitalized for Severe Depression
An eight-week, randomized, double blind, two parallel groups, study to assess clinical response of duloxetine 60 milligrams (mg) and 120 mg per day in patients hospitalized for severe depression.
- Trial name
- NCT00422162
- Testing
- Duloxetine hydrochloride
- Where
- 35 sites in France, Italy and 2 more
- Volunteers
- 339 people
- Sponsor
- Eli Lilly and Company
Schizophrenia, Schizoaffective Disorder
Progressively Decreasing Titration Schedules of Bifeprunox in Subjects With Schizophrenia or Bipolar Disorder
This study is to assess the tolerability of bifeprunox with the progressive elimination of titration steps to achieve the shortest tolerated titration dosing to a dose of 40 mg/day in either schizophrenia or bipolar disorder…
- Conditions
- Schizophrenia, Schizoaffective Disorder, Bipolar Disorder
- Trial name
- NCT00139919
- Testing
- Bifeprunox
- Where
- United States
- Sponsor
- Solvay Pharmaceuticals
Major Depressive Disorder
Study to Explore the Effective Doses and to Assess the Safety and Efficacy of Hypidone Hydrochloride Tablets
The objective of this study is to evaluate the safety and efficacy of Hypidone Hydrochloride tablets in treatment of patients with major depressive disorder (MDD) by evaluating the change of MADRS total scores from baseline to…
- Trial name
- NCT03739632
- Testing
- Hypidone Hydrochloride tablets
- Where
- 19 sites in China
- Volunteers
- 240 people
- Sponsor
- Zhejiang Huahai Pharmaceutical Co., Ltd.
Major Depressive Episode
Retrospective Observational Study DIANA Study
This Non-Interventional Study (NIS) is intended to evaluate the duration of treatment with an initial antidepressant taken as monotherapy in patients in whom treatment was changed because of suboptimal response at physician's…
- Trial name
- DIANA (NCT01976793)
- Where
- 8 sites in Russia
- Volunteers
- 450 people
- Sponsor
- AstraZeneca
Schizophrenia
A Study of Extended Release Extended-release (ER) OROS Paliperidone Tolerability, as Compared to Immediate-release (IR)Risperidone, in Patients With Schizophrenia
The purpose of this study is a noninferiority comparison of the orthostatic tolerability of a dose of 12 mg extended-release (ER) OROS paliperidone with the current recommended initial titration dose (2 mg) of immediate-release…
- Trial name
- NCT00791232
- Testing
- extended-release (ER) OROS paliperidone
- Volunteers
- 113 people
- Sponsor
- Johnson & Johnson Pharmaceutical Research & Development, L.L.C.
Major Depressive Disorder
A Safety, Efficacy and Biomarker Study of JNJ-42847922 in Participants With Major Depressive Disorder
The purpose of this study is to evaluate the safety and tolerability of JNJ-42847922 in participants with Major Depressive Disorder (MDD).
- Trial name
- NCT02476058
- Testing
- JNJ-42847922, Diphenhydramine
- Where
- 7 sites in Belgium, Germany and 1 more
- Volunteers
- 48 people
- Sponsor
- Janssen-Cilag International NV
Mood and Sleep Quality
A Study to Evaluate the Efficacy of VL-NL-02 on Sleep Quality.
The goal of this clinical trial is to study the impact of VL-NL-02 in improving sleep quality, restorative sleep complaints, quality of life, stress levels, and sleep stages.
- Trial name
- NCT06056258
- Testing
- VL-NL-02
- Where
- 5 sites in India
- Volunteers
- 48 people, healthy volunteers welcome
- Sponsor
- Vedic Lifesciences Pvt. Ltd.
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.